Literature DB >> 28320094

lncRNA MEG3 had anti-cancer effects to suppress pancreatic cancer activity.

Lei Gu1, Jiaqiang Zhang1, Minmin Shi1, Qian Zhan1, Baiyong Shen1, Chenghong Peng2.   

Abstract

AIM: The aim of this study was to explain the mechanism of lncRNA MEG 3 in pancreatic cancer.
METHODS: We were collecting 30 pancreatic cancer patients, taking the sample from these patients. We measured the PI3K protein expressions from 30 patients by IHC and WB methods and MEG 3 expression by RT-PCR, and analyzed the relationship between PI3K protein expression and pancreatic cancer patients' clinical pathology and the correlation between lncRNA MEG 3 and PI3K. In the cell experiment, PANC-1 cells were divided into three groups: NC, BL and lncRNA groups, after treatment,we measured cell proliferation rate of 3 groups by MTT methods, evaluated cell apoptosis and cell cycle using flow cytometry, tested the invasion cells and migrate rate of 3 groups by transwell and wound healing assays.
RESULTS: Compared with carcinoma adjacent tissue, The PI3K protein expression of pancreatic cancer tissue were significantly up-regulation (P>0.05). MEG 3 gene expression was negatively correlated with PI3K expression. The MEG 3 was negatively correlated with tumor size, Metastasis and Vascular invasion in pancreatic cancer (P<0.05, respectively). In the cell experiment, The cell proliferation and apoptosis rates of lncRNA group were significantly difference compared with NC group (P<0.05, respectively), and the G1 phase rate of lncRNA group was higher than NC group (P<0.05). The invasion cells and wound healing rate were significantly reduced in lncRNA group than those in NC group (P<0.05, respectively).
CONCLUSION: MEG 3 over-expressing had anti-cancer effects to suppress pancreatic cancer activity by regulation PI3K/AKT/Bcl-2/Bax/Cyclin D1/P53 and PI3K/AKT/MMP-2/MMP-9 signaling pathways.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  AKT; Bax; Bcl-2; Cyclin D1; MEG 3; MMP-2; MMP-9; P53; PI3K

Mesh:

Substances:

Year:  2017        PMID: 28320094     DOI: 10.1016/j.biopha.2017.02.041

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  21 in total

1.  Long non-coding RNA MEG3 regulates proliferation, apoptosis, and autophagy and is associated with prognosis in glioma.

Authors:  Haikang Zhao; Xin Wang; Xiaoyun Feng; Xiaoqiang Li; Li Pan; Jianrong Liu; Fenglu Wang; Zhihai Yuan; Lei Yang; Jun Yu; Rujuan Su; Yuelin Zhang; Lianting Ma
Journal:  J Neurooncol       Date:  2018-10-03       Impact factor: 4.130

2.  A Cancer Cell Cluster Marked by LincRNA MEG3 Leads Pancreatic Ductal Adenocarcinoma Metastasis.

Authors:  Hong Pan; Huanrong Diao; Wen Zhong; Taifang Wang; Ping Wen; Chunli Wu
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

3.  LncRNA BC032020 suppresses the survival of human pancreatic ductal adenocarcinoma cells by targeting ZNF451.

Authors:  Zhipeng Zhang; Hongxi Chen; Yebin Lu; Tiecheng Feng; Weijia Sun
Journal:  Int J Oncol       Date:  2018-02-28       Impact factor: 5.650

Review 4.  Potential applications of MEG3 in cancer diagnosis and prognosis.

Authors:  Yuqing He; Yanhong Luo; Biyu Liang; Lei Ye; Guangxing Lu; Weiming He
Journal:  Oncotarget       Date:  2017-08-04

5.  Deregulation of the imprinted DLK1-DIO3 locus ncRNAs is associated with replicative senescence of human adipose-derived stem cells.

Authors:  Silvia García-López; Carmen Albo-Castellanos; Rocio G Urdinguio; Susana Cañón; Fátima Sánchez-Cabo; Alberto Martínez-Serrano; Mario F Fraga; Antonio Bernad
Journal:  PLoS One       Date:  2018-11-05       Impact factor: 3.240

6.  High expression of TMEM40 contributes to progressive features of tongue squamous cell carcinoma.

Authors:  Qingyan Zhang; Danhui Huang; Zhenfei Zhang; Yuzhen Feng; Meiting Fu; Min Wei; Jueyu Zhou; Yuanjin Huang; Shuguang Liu; Rong Shi
Journal:  Oncol Rep       Date:  2018-10-12       Impact factor: 3.906

Review 7.  Targeting PI3K in cancer: mechanisms and advances in clinical trials.

Authors:  Jing Yang; Ji Nie; Xuelei Ma; Yuquan Wei; Yong Peng; Xiawei Wei
Journal:  Mol Cancer       Date:  2019-02-19       Impact factor: 27.401

Review 8.  Role of non-coding RNA in pancreatic cancer.

Authors:  Yinghao Lv; Shuai Huang
Journal:  Oncol Lett       Date:  2019-08-16       Impact factor: 2.967

Review 9.  Long noncoding RNAs: role and contribution in pancreatic cancer.

Authors:  K T Ramya Devi; Dharshene Karthik; TharunSelvam Mahendran; M K Jaganathan; Sanjana Prakash Hemdev
Journal:  Transcription       Date:  2021-05-26

10.  Subgroup analysis reveals molecular heterogeneity and provides potential precise treatment for pancreatic cancers.

Authors:  Heying Zhang; Juan Zeng; Yongqiang Tan; Lin Lu; Cheng Sun; Yusi Liang; Huawei Zou; Xianghong Yang; Yonggang Tan
Journal:  Onco Targets Ther       Date:  2018-09-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.